Abstracts tagged "juvenile idiopathic arthritis (JIA) and remission"

Abstract Number: 2388 • 2018 ACR/ARHP Annual Meeting
Assessment of Treatment Responses, with Special Reference to Remission Using Juvenile Arthritis Disease Activity Score (JADAS), in the Different Categories of Juvenile Idiopathic Arthritis
Debanjali Sinha¹, Sumantro Mondal¹ and Alakendu Ghosh², ¹Rheumatology, Senior Resident (Academic), Kolkata, India, ²Rheumatology, Professor and Head of Department, Kolkata, India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) isthe most common chronic rheumatologic disease in children, which can significantly compromise quality of life. The objective of the study…
Abstract Number: 2449 • 2015 ACR/ARHP Annual Meeting
Does Antinuclear Antibodies Predict Remission in JIA ?
Mia Glerup¹, Troels Herlin² and Marinka Twilt³, ¹Pediatrics, Aarhus University Hospital, Skejby, Aarhus, Denmark, ²Department of Pediatrics, Århus University Hospital Skejby, Århus, Denmark, ³Rheumatology, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: In the recent years the classification of Juvenile Idiopathic Arthritis (JIA) according to the ILAR criteria has been questioned as some categories still include…
Abstract Number: 3181 • 2015 ACR/ARHP Annual Meeting
How Common Is Inactive Disease in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis? the Importance of Definition
Stephanie Shoop¹, Suzanne M. Verstappen², Eileen Baildam³, Alice Chieng⁴, Joyce Davidson^5,6, Helen Foster⁷, Yiannis Ioannou⁸, Flora McErlane⁷, Lucy R Wedderburn⁹, Wendy Thomson¹⁰ and Kimme L. Hyrich¹⁰, ¹ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, The University of Manchester, M13 9PT, United Kingdom, ²ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, the University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁵The Royal Hospital for Sick Children, Glasgow, Glasgow, United Kingdom, ⁶The Royal Hospital for Sick Children, Edinburgh, Edinburgh, United Kingdom, ⁷Royal Victoria Hospital, Newcastle, United Kingdom, ⁸Rayne Institute, University College London, London, UK, London, United Kingdom, ⁹Great Ormond Street Hospital NHS Foundation Trust, Paediatric Rheumatology, London, United Kingdom, ¹⁰arc Epidemiology Unit, Manchester, United Kingdom
Background/Purpose: Patients with JIA are at risk of disability, pain and joint damage in the longer-term. Treating toward clinically inactive disease (ID) has the potential…
Abstract Number: 278 • 2014 ACR/ARHP Annual Meeting
Is It Worth Allowing the Presence of Morning Stiffness in the Definition of Inactive Disease in Juvenile Idiopathic Arthritis?
Alessandro Consolaro¹, Maddalena Allegra², Maria C. Gallo¹, Benedetta Schiappapietra², Serena Calandra¹, Cristina Robbiano², Federica Mongelli³, Cecilia Bava³, Alberto Martini^2,3 and Angelo Ravelli^4,5, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Istituto Giannina Gaslini, Genova, Italy, ³University of Genova, Genova, Italy, ⁴Istituto Gaslini-PRINTO, Genova, Italy, ⁵Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose Morning stiffness is a major symptom of juvenile idiopathic arthritis (JIA) and it is usually associated with active disease. However, it is common view…
Abstract Number: 1165 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Nicoletta Solari¹, Elena Palmisani¹, Alessandro Consolaro¹, Sara Dalprà¹, Benedetta Schiappapietra¹, Giulia Bracciolini¹, Silvia Rosina¹, Giorgia Negro¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The advent of new therapies for juvenile idiopathic arthritis (JIA), particularly the introduction of biologic medications, has increased considerably the potential for treatment benefit,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].